Litifilimab: AMETHYST Phase 3 Part B results
AMETHYST Phase 2 Part A already met its primary endpoint and has public 52-week follow-up. Biogen's October update expects results from the separate Phase 3 part in H1 2027. The forward candidate is the Phase 3 report, not another vote on the known Part A outcome.
BiogenDrug catalystsClinical data publicationDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Phase 2 Part A result is already known; do not reuse its primary outcome as an unresolved future question.
- H1 2027 is an expected publication window, not an exact date or approved contract deadline.
- Research only. Verify the precise Phase 3 Part B endpoint/analysis and latest sponsor status before promotion.
Primary evidence
Sponsor expectation: H1 2027 — exact day unconfirmed
Biogen · Phase 2 known; Phase 3 AMETHYST outlookPublished 2026-10-02
ClinicalTrials.gov · NCT05531565Published 2026-10-23
ClinicalTrials.gov API · NCT05531565Published 2026-10-23
Potential outcome market
Will Biogen publicly report the prespecified Phase 3 Part B AMETHYST analysis by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.